Gilead Has Full HIV Policy Agenda For 2019: Part D Challenge; Prophylaxis Increase
Executive Summary
Gilead faces two-pronged policy challenge in its core HIV business: its Part D product line could lose protections, but prophylactic prescriptions could dramatically expand under the Trump Administration's plan to eliminate HIV transmission.
You may also be interested in...
US Initiative To End HIV Epidemic Will Boost PrEP Access
'Number of different initiatives' coming in next several months to make drugs more affordable, including for PrEP prophylaxis, HHS Assistant Secretary for Health Giroir says. Multi-agency approach is key strategy.
Carrots Or Sticks: Which Way Might Medicare's Protected Classes Reforms Go?
UnitedHealthcare program for commercial members offers some implications. MyScripRewards encourages less costly HIV treatments using financial rewards, underscoring insurers’ tendency to favor carrots over sticks when it comes to coverage policies for such drugs.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.